Trial Profile

A Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory Dysfunction

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary) ; Dexamethasone; Enoxaparin sodium; Remdesivir
Indications COVID 2019 infections; COVID-19 respiratory infection
Focus Adverse reactions

Most Recent Events

02 Aug 2023 According to an Enlivex Therapeutics media release, data from this study were peer-reviewed published in Frontiers in Immunology.
02 Aug 2023 Results presented in an Enlivex Therapeutics media release.
03 Feb 2021 Results presented in an Enlivex Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com